Borggrefe M, Breithardt G, Podczeck A, Rohner D, Budde T, Martinez-Rubio A
Department of Internal Medicine C, Hospital of the University of Münster, F.R.G.
Eur Heart J. 1989 Jul;10(7):591-601. doi: 10.1093/oxfordjournals.eurheartj.a059536.
Catheter ablation of ventricular tachycardia (VT) was attempted in 24 patients (mean age 49 +/- 15.1 years) with a history of recurrent sustained VT resistant to previous antiarrhythmic drug therapy. 14 patients (58.3%) had also failed to respond to long-term administration of amiodarone alone and in combination with class I antiarrhythmic drugs. Endocardial catheter mapping during induced or spontaneous VT and/or pacemapping were performed to identify the site of origin of VT. Direct-current high-energy anodal shocks were delivered from a conventional cardioverter with stored energies of 100, 200 or 400 J via the distal electrode of conventional catheters. A total of 139 shocks was delivered during the ablation procedure. One patient died from wall perforation. Within 1 week of ablation, nine patients developed spontaneous recurrences of monomorphic sustained VT, identical to the clinical VT, and one patient developed a VT with a new morphology. In addition, four patients had a recurrence of their clinical VT after several weeks. In seven of 14 patients with spontaneous recurrences after the first ablation procedure and in three patients in whom VT was again inducible at the end of the first week, a second ablation procedure was performed. One patient with inducible VT after the first and second ablation sessions was given a third ablation procedure, and was discharged from hospital on anti-arrhythmic drugs which were successful despite being previously ineffective. After a mean follow-up period of 14.1 +/- 9.1 months, there were no spontaneous recurrences of sustained VT in 17 patients (71%) (nine without antiarrhythmic drugs and eight on antiarrhythmic drugs). In the remaining patients, incessant non-sustained VT (n = 2) or recurrent sustained VT (n = 2) occurred, and two patients died suddenly (at 2 and 21 months). There was no correlation between catheter mapping data or the results of pre-discharge electrophysiological study and clinical outcome during long-term follow-up. Complications related to catheter ablation included pulmonary oedema, cardiac tamponade, femoral artery occlusion, multiple episodes of ventricular tachycardia/fibrillation and thrombus formation, each in one patient (major complications; n = 7,29.1%), as well as transient third degree AV block, transient right or left bundle branch block, transient marked ST elevation or transient atrial tachycardia (minor complications; n = 8, 33.3%). The results suggest that catheter ablation might become an effective procedure for the non-pharmacological treatment of sustained VT.(ABSTRACT TRUNCATED AT 400 WORDS)
对24例(平均年龄49±15.1岁)有复发性持续性室性心动过速(VT)病史且对既往抗心律失常药物治疗无效的患者尝试进行导管消融术。14例患者(58.3%)单独长期服用胺碘酮以及联合Ⅰ类抗心律失常药物均无效。在诱发或自发VT期间进行心内膜导管标测和/或起搏标测,以确定VT的起源部位。通过传统导管的远端电极,从储存能量为100、200或400 J的传统心脏复律器输送直流高能阳极电击。消融过程中共进行了139次电击。1例患者死于心脏穿孔。消融术后1周内,9例患者出现与临床VT相同的单形性持续性VT自发复发,1例患者出现形态学不同的VT。此外,4例患者在数周后出现临床VT复发。在首次消融术后自发复发的14例患者中的7例以及在第一周结束时VT再次可诱发的3例患者中,进行了第二次消融术。1例在第一次和第二次消融术后VT仍可诱发的患者接受了第三次消融术,出院时服用抗心律失常药物,尽管之前无效,但此次成功。平均随访14.1±9.1个月后,17例患者(71%)(9例未服用抗心律失常药物,8例服用抗心律失常药物)未出现持续性VT自发复发。其余患者出现无休止性非持续性VT(n = 2)或复发性持续性VT(n = 2),2例患者猝死(分别在2个月和21个月时)。导管标测数据或出院前电生理研究结果与长期随访期间的临床结局之间无相关性。与导管消融相关的并发症包括肺水肿、心脏压塞、股动脉闭塞、多次室性心动过速/心室颤动发作和血栓形成,各1例患者(主要并发症;n = 7,29.1%),以及短暂性三度房室传导阻滞、短暂性右或左束支传导阻滞、短暂性明显ST段抬高或短暂性房性心动过速(次要并发症;n = 8,33.3%)。结果表明,导管消融术可能成为持续性VT非药物治疗的有效方法。(摘要截断于400字)